In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model

Si,Chunfeng; Xu,Maolei; Lu,Meiyu; Yu,Yan; Yang,Meizi; Yan,Miaomiao; Zhou,Ling; Yang,Xiaoping

doi:10.3892/ol.2017.7169

In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model

Authors:
- Chunfeng Si
- Maolei Xu
- Meiyu Lu
- Yan Yu
- Meizi Yang
- Miaomiao Yan
- Ling Zhou
- Xiaoping Yang
View Affiliations

Affiliations: Key Laboratory of Traditional Chinese Medicine Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: October 11, 2017 https://doi.org/10.3892/ol.2017.7169
Pages: 7391-7397
Copyright: © Si et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer cell vaccines with strong specificity and low tolerance have been revealed to be a promising option for oncology treatment. Various antigen forms, including tumor cell lysate and glutaraldehyde‑fixed tumor cells, have been intensively used in cancer vaccine preparation. However, the most effective antigen form has not yet been identified. In the present study, the antitumor efficiency of vaccines prepared by these two antigen forms was systematically investigated. Murine H22 hepatocellular carcinoma cell lysate and glutaraldehyde‑fixed H22 hepatocellular carcinoma cells were conjugated with Freund's adjuvant to prepare vaccines, H22‑TCL and Fixed‑H22‑CELL, respectively. H22‑TCL and Fixed‑H22‑CELL were administrated by subcutaneous immunization in prophylactic and therapeutic strategies. The results of the present study revealed that H22‑TCL immunization induced more significant inhibition on tumor growth and metastasis compared with Fixed‑H22‑CELL injection. Furthermore, histopathological observation demonstrated that H22‑TCL vaccine induced larger areas of continuous necrosis within tumors compared to the Fixed‑H22‑CELL vaccine, which was associated with the extent of tumor inhibition. More importantly, the H22‑TCL vaccine injection elicited more evident antigen‑specific antibody responses compared with the Fixed‑H22‑CELL injection. Splenocytes from H22‑TCL vaccinated mice also exhibited a more significant T lymphocytes proliferation compared with that from Fixed‑H22‑CELL‑treated mice. All the results indicated that whole tumor cell lysate may be a more effective antigen form in cancer vaccine preparation compared with glutaraldehyde‑fixed tumor cells, which elicited more marked antigen specific humoral and cellular immune responses resulted with a superior antitumor efficiency. This would have important clinical signification for cancer vaccine preparation and serve a role in prompting this to other researchers.

View Figures

View References

1	Ray K: Liver cancer: The promise of new approaches in the management of hepatocellular carcinoma-adding to the toolbox? Nat Rev Gastroenterol Hepatol. 10:1952013. View Article : Google Scholar : PubMed/NCBI
2	Dong B, Dai G, Xu L, Zhang Y, Ling L, Sun L and Lv J: Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes. Mol Med Rep. 10:2827–2834. 2014. View Article : Google Scholar : PubMed/NCBI
3	Grotz TE, Kottschade L, Pavey ES, Markovic SN and Jakub JW: Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: A single-center Study. Am J Clin Oncol. 37:467–472. 2014. View Article : Google Scholar : PubMed/NCBI
4	Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, Jung NC, Lee WB, Lee HS, Bae YS and Onji M: Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol. 41:1601–1609. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chen IJ, Yen CF, Lin KJ, Lee CL, Soong YK, Lai CH and Lin CT: Vaccination with OK-432 followed by TC-1 tumor lysate leads to significant antitumor effects. Reprod Sci. 18:687–694. 2011. View Article : Google Scholar : PubMed/NCBI
6	Huang L and Ohno T: Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model. Cancer Lett. 202:153–159. 2003. View Article : Google Scholar : PubMed/NCBI
7	Novaković S, Stegel V, Kopitar A, Ihan A and Novaković BJ: Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine. 25:8241–8256. 2007. View Article : Google Scholar : PubMed/NCBI
8	Suckow MA, Rosen ED, Wolter WR, Sailes V, Jeffrey R and Tenniswood M: Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine. Cancer Immunol Immunother. 56:1275–1283. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yin W, He Q, Hu Z, Chen Z, Qifeng M, Zhichun S, Zhihui Q, Xiaoxia N, Li J and Gao J: A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer. Vaccine. 28:4937–4944. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wang ZY, Xing Y, Liu B, Lu L, Huang X, Ge CY, Yao WJ, Xu ML, Gao ZQ, Cao RY, et al: Protective antitumor immunity induced by tumor cell lysates conjugated with diphtheria toxin and adjuvant epitope in mouse breast tumor models. Chin J Cancer. 31:295–305. 2012. View Article : Google Scholar : PubMed/NCBI
11	Xu M, Zhou L, Zhang P, Lu Y, Ge C, Yao W, Xing Y, Xiao W, Dong Y, Wu J, et al: Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine. Tumour Biol. 34:3173–3182. 2013. View Article : Google Scholar : PubMed/NCBI
12	Copier J and Dalgleish A: Whole-cell vaccines: A failure or a success waiting to happen? Curr Opin Mol Ther. 12:14–20. 2010.PubMed/NCBI
13	Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK and Brennan MF: A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 52:1964–1972. 2007. View Article : Google Scholar : PubMed/NCBI
14	Fernandez P, Petres S, Mécheri S, Gysin J and Scherf A: Strain-transcendent immune response to recombinant Var2CSA DBL5-ε domain block P. falciparum adhesion to placenta-derived BeWo cells under flow conditions. PLoS One. 5:e125582010. View Article : Google Scholar : PubMed/NCBI
15	Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R and Min W: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 17:343–348. 1999. View Article : Google Scholar : PubMed/NCBI
16	Xu M, Xing Y, Zhou L, Yang X, Yao W, Xiao W, Ge C, Ma Y, Yang J, Wu J, et al: Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant. Tumour Biol. 34:1399–1408. 2013. View Article : Google Scholar : PubMed/NCBI
17	Fowlkes V, Wilson CG, Carver W and Goldsmith EC: Mechanical loading promotes mast cell degranulation via RGD-integrin dependent pathways. J Biomech. 46:788–795. 2013. View Article : Google Scholar : PubMed/NCBI
18	Ozturk M and Oter S: Molecular approach to treatment of hepatocellular carcinoma: New hope for therapeutic targets. J Exp Integr Med. 1:83–84. 2011. View Article : Google Scholar
19	Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013. View Article : Google Scholar : PubMed/NCBI
20	Elert E: Calling cells to arms. Nature. 504:S2–S3. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yuan X, Li W, Cui Y, Zhan Q, Zhang C, Yang Z, Li X, Li S, Guan Q and Sun X: Specific cellular immune response elicited by the necrotic tumor cell-stimulated macrophages. Int Immunopharmacol. 27:171–176. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kawahara M and Takaku H: Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice. Int J Oncol. 43:2023–2030. 2013. View Article : Google Scholar : PubMed/NCBI
23	He A, Zhang W, Xu K, Wang J, Yang Y and Chao X: Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine. Med Oncol. 29:2261–2269. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ishii Y, Sakamoto T, Ito R and Yanaga K: Anti-angiogenic therapy on hepatocellular carcinoma development and progression. J Surg Res. 158:69–76. 2010. View Article : Google Scholar : PubMed/NCBI
25	Liang Y and Sun H: The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita. Int J Clin Exp Med. 8:6914–6925. 2015.PubMed/NCBI